Sign In
Buy XLV
$152.18
+2.12 (+1.41%)
At Close: Jun 23, 2026
Yield Curve Inverts: 4 Value Sector ETFs to Play
09:15am, Friday, 17'th Jun 2022
The yield on the 3-year Treasury yield was higher than the 10-year U.S. treasury yield. As the yield curve inverted, play these sector ETFs.
XLV, XBI: Why We're Bullish On Healthcare (Generally) And Biotech (Specifically)
03:41am, Friday, 17'th Jun 2022
In spite of half of our FMP's four building blocks trading in distress-mode, the portfolio/investment strategy is working just fine. Although stocks are no longer expensive, the economy is looking so
Biggest U.S. Rate Hike Since 1994 in June: 4 ETFs to Win
09:18am, Thursday, 16'th Jun 2022
In line with the market expectations, the Federal Reserve increased its benchmark interest rate by 75 bps yesterday.
Buy the Dip With These Top-Ranked ETFs
02:40pm, Wednesday, 15'th Jun 2022
The S&P 500 entered into a bear market. Buy the dip with these ETFs.
1970s-Style Stagflation in the Cards? ETF Strategies to Win
09:02am, Thursday, 09'th Jun 2022
The market is rife with high inflation risks and lower growth, meaning a stagflationary scenario for the most developed economies, including the United States.
5 Top-Ranked Safe ETF Plays for Those Fearing Market Turmoil
09:04pm, Thursday, 02'nd Jun 2022
Against the current backdrop, we highlight some top-ranked ETFs that can be relatively safer bets either backed by their nature or favorable external factors.
Healthcare Outperformance May Signal Short-Term Market Bottom
03:49pm, Monday, 23'rd May 2022
This sector outperformance may be a sign the market is nearing a point of selling exhaustion.
Top Sector ETFs to Play Despite S&P 500's Still-Pricey Valuation
02:17pm, Monday, 16'th May 2022
Wall Street was off to the worst start to a year since 1939 and the global market selloff will continue, according to Bank of America Corp. and Morgan Stanley, as quoted on Bloomberg.
AbbVie: Buy, Hold, Or Sell After Q1 Results?
01:00pm, Sunday, 08'th May 2022 Seeking Alpha
AbbVie stock was under heavy selling pressure following its Q1 ‘22 earnings. Check out whether ABBV stock is a buy, hold or sell after its Q1 earnings.
Defensive ETFs Are Turning Heads as Investors Seek Safer Plays
04:54pm, Friday, 06'th May 2022
Defensive sector-related exchange traded funds have been a popular play among investors seeking a relatively safe area in which to sit out the global market turmoil. According to Morningstar data, ETF
Is Pfizer Too Dependent on COVID-19 Revenue?
03:30pm, Friday, 06'th May 2022 The Motley Fool
How strong is the rest of the company's portfolio?
ETFs had outflows in April for the first time in almost 3 years — but here are some bright spots in the market tumult
08:28pm, Thursday, 05'th May 2022 MarketWatch
Market volatility remains elevated after last month outflows in exchange traded-funds listed in the U.S. for the first time in almost three years, according to State Street Global Advisors.
3 Growth Stocks That Beat Earnings Despite Inflation
03:15pm, Thursday, 05'th May 2022 The Motley Fool
Macroeconomic factors have challenged a lot of companies lately -- but these three companies have succeeded anyway.
Here's How Abbott Laboratories Increased Its Profits by 37% in Q1
02:30pm, Thursday, 05'th May 2022 The Motley Fool
The strong quarter wasn't just due to an increase in COVID-19 revenue.
Getting Defensive, Investors Shift Sector Focus in April
01:19pm, Thursday, 05'th May 2022
Stock market volatility remained high in April, leading advisors to look more into defensive sector ETFs. In April, six U.S. sector focused ETFs were among the 20 most viewed tickers on the ETF Databa
